William Wierda, MD | Authors


Dr. William Wierda on Ibrutinib and Idelalisib as Treatments in NSCLC

December 09, 2015

William G. Wierda, MD, PhD, discusses ibrutinib and idelalisib as treatments for non-small cell lung cancer. Wierda says that as it currenlty stands, ibrutinib is approved only for patients with NSCLC with a 17p deletion untreated and idelalisib is only approved for patients with untreated NSCLC.